The US Food and Drug Administration (FDA) has approved GSK’s triazaacenaphthylene antibiotic, Blujepa (gepotidacin), for ...

Stock analysts at Zacks Research upped their FY2027 earnings per share estimates for GSK in a report issued on Tuesday, March ...

For much of her early career, Shobie Ramakrishnan called Silicon Valley home. GSK’s chief digital and technology officer ...

The FDA approval is based on late-stage data, which shows that GSK's Blujepa is at least as effective as a leading standard treatment for uncomplicated UTIs.

GSK’s Blujepa receives US FDA nod to treat uncomplicated urinary tract infections in female and paediatric patients 12 years of age and older: Philadelphia Friday, March 28, 202 ...

GSK received approval from the Food and Drug Administration for Blujepa to be used as a treatment for some urinary tract infections. Blujepa, or gepotidacin, was approved to treat uncomplicated ...

The FDA has approved GSK’s Blujepa for the treatment of female adults and pediatric patients with uncomplicated urinary tract ...

The FDA approved GSK's Blujepa for uncomplicated UTIs in female adults and pediatric patients, with phase 3 trials showing strong efficacy vs. nitrofurantoin.

UK pharma major GSK (LSE: GSK) today announced a major new research collaboration with the UK Dementia Research Institute (UK ...

Blujepa, which is made by the British pharmaceutical company GSK plc, is approved for the treatment of women and children ...

That involved working with GSK’s R&D, supply chain, and commercial units, to use data in a way that made sense for the company. Ramakrishnan says the company was an “early thinker” in ...

A U.S. commercial launch of Blujepa is planned for the second half of this year, GSK said. Undervalued high-quality names from the Morningstar Wide Moat Focus Index are attractive stocks to buy ...